Track Speakers include: 

  • Manuela C. Matesan, MD, PhD; University of Washington
  • Jonathan McConathy, MD, PhD; University of Alabama, Birmingham
  • Satoshi Minoshima, MD, PhD; University of Utah
  • Romina Mizrahi, MD, PhD; PET Center, CAMH
  • Karina Mosci, MD; Hospita Das Forcas Armadas (HFA)
  • James M. Mountz, MD, PhD; University of Pittsburgh Medical Center
  • Victor William Pike, PhD; National Institute of Mental Health
  • Julie C. Price, PhD; Massachusetts General Hospital
  • David Russell, MD, PhD; Yale School of Medicine, Institute for Neurodegenerative Disorders
  • Daniel H. Silverman, MD, PhD; UCLA
  • Carolyn Beebe Smith, PhD; National Institute of Mental Health
  • Andrei G. Vlassenko, MD, PhD; Washington University
  • Igor Yakushev, MD; Technical University of Munich
  • Lionel S. Zuckier, MD, MBA, FRCPC; Montefiore Hospital
  • Katherine Zukotynski, BASc, MD, FRCPC; McMaster University

Neuroimaging Track

This program has been carefully prepared to improve knowledge in Neuroimaging, starting from basic concepts to more advanced applications, addressing several important subjects. In addition, participants will have the opportunity to send challenging cases to be presented and discussed in a "Read with Experts Session." Topics include:

Thursday, January 23

Basics in Neuroimaging:  Anatomy, Radiotracers and Best Practices
The session will be directed to residents, nuclear medicine physicians as well as technologists interested in improving their knowledge in Nuclear Medicine Neuroimaging. Presentations will address in a clear and didactic way the most utilized neuroimaging radiotracers, provide review in neuroanatomy focusing on image interpretation, discuss best practices, imaging artifacts and how to better perform SPECT and PET studies.

Presentations include:
  • Neuroimaging Radiotracers (PET/SPECT)
  • Neuroanatomy for Imaging Interpretation
  • Best Practices, Imaging Artifacts and Pitfalls
  • Operationalizing your SPECT and PET Brain Imaging: Technologist perspective

Improve your knowledge in PET Quantification and Artificial Intelligence

Summary: The session will be directed to residents and nuclear medicine physicians interested in expanding their knowledge in quantification applications and Artificial Intelligence. The session will explain the importance and how to use software imaging interpretation for clinical purposes, as well as discuss full quantification applicability. Notions of Artificial Intelligence in Neuroimaging will also be provided.

Presentations include:
  • Software Imaging Interpretation
  • Diagnostic Statistical Mapping (3D-SSP/SPM)
  • Understanding Full Quantification
  • Artificial Intelligence

Planar to Hybrid Brain Imaging
The session will provide a historical review and update on the clinical applications of Nuclear Medicine in Neurology, addressing planar, SPECT and Hybrid Imaging techniques.

Presentations include:

  • Cisternography and Shunt Patency
  • Brain Death
  • SPECT for Brain Applications
  • PET/MR for Brain Applications

Friday, January 24

Neurodegeneration:  FDG-PET for Dementia
The session will be directed to residents, nuclear medicine physicians as well as technologists interested in improving their knowledge in Nuclear Medicine Neuroimaging. 

This session begins with an overview of the A/T/N staging system for dementia biomarkers. Then we will concentrate on a structured approach to interpreting FDG-PET for differentiating the various dementias. We will conclude with our neurology colleague providing the clinical perspective on the role of imaging for dementia

Presentations include:

  • Setting the Stage for Dementia Biomarkers (A/T/N)
  • Structured Method for the Interpretation of FDG PET
  • Neurologist’s Perspective on Imaging for Dementia 

MRI, Amyloid PET, and Tau PET:  The current status 
This session will provide an overview of the current status of MRI, amyloid PET, and tau PET, with a primary focus on Alzheimer’s disease.  This continuing education session will review current findings and advancements that have improved our understanding of brain aging, of early disease detection, and AD disease progression.  This will include reviews of MRI methods and sequences used for clinical and research applications and MRI findings of cortical atrophy and thinning along the AD spectrum.  This will also include discussion of PET methods and challenges encountered in amyloid PET and tau PET, of relative performance characteristics across different amyloid and tau radiotracers, and current findings on in vivo relationships between amyloid and tau at baseline and over time.  The AT(N) classification system of biomarker grouping (i.e., amyloid, tau, and neurodegeneration) will also be discussed.  Altogether, these topics will inform on methods, applications, and findings relevant for in vivo disease staging, differential diagnosis, and important considerations for clinical trial study design.

Presentations include:

  • ”An MRI scan complements and enhances the clinical diagnosis of Alzheimer’s disease and other dementing disorders””. Clinic and MRI in AD
  • Amyloid Imaging
  • Tau Imaging 

Movement Disorders
The session will be directed to residents, nuclear medicine physicians as well as technologists interested in improving their knowledge in Nuclear Medicine Neuroimaging. 

Movement disorders can be caused be a very wide differential of diseases. Neurologists must consider many factors in deciding when imaging is appropriate and then subsequently how to integrate the results into patient management. Dopamine transporter (DaT) SPECT has high accuracy for evaluation of possible Parkinsonian syndromes, but the success of a program relies on optimal performance and interpretation. PET can be very useful in the work-up of movement disorders and requires appropriate selection of both the patient and radiotracer.

Presentations include:

  • Neurologist’s Perspective on Imaging for Movement Disorders
  • Optimizing your Dopamine Transporter SPECT Program
  • PET in the Evaluation of Movement Disorders

Brain Tumors and Encephalitis
Nuclear Neuroimaging is becoming an important diagnostic tool with increasing impact in neurological and neuro-oncological practice. An emerging use of brain FDG-PET is the early recognition of a potentially treatable cause of rapid progressive dementia. This is the case of Autoimmune Limbic Encephalitis, where brain FDG-PET findings may appear even before characteristic brain MRI hyperintensities. On the other hand, PET is a well-established method in systemic oncology, and is being increasingly used to supplement MRI in the clinical management of brain tumors. The evidence-based recommendation by the PET- Response Assessment in Neuro-Oncology working group (RANO) and the European Association of Neuro-Oncology (EANO) on the clinical use of PET imaging in gliomas, and the recently published joint guidelines of the SNMMI and EANM focusing on radiotracers that are used in clinical practice imaging, i.e. glucose metabolism, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), and system L amino acid transport ([11C-methyl]-methionine (MET), O-(2-[18F]fluoroethyl)-L-tyrosine (FET) and 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA).

Presentations include:

  • Emerging Use of Brain FDG-PET in Autoimmune Limbic Encephalitis
  • The Role of Nuclear Medicine in the Management of Brain Tumors
  • Brain Tumors Case Presentation


Saturday, January 25

Molecular Imaging in Traumatic Brain Injury and Epilepsy
The session will be directed to residents, nuclear medicine physicians as well as technologists interested in improving their knowledge of molecular imaging in traumatic brain injury and epilepsy. This session begins with an overview of the molecular imaging for brain trauma.  Then we will focus on the application of ictal / interictal SPECT and PET imaging for localization of seizure focus in patients with medically refractory epilepsy before surgical intervention.  We will review the concepts and information that a nuclear physician needs to know to improve the performance and interpretation of epilepsy-related nuclear medicine exams. 

Presentations include:

  • Imaging of Brain Trauma
  • SPECT in Epilepsy
  • PET in Epilepsy

The session will be directed to residents, nuclear medicine physicians as well as technologists interested in improving their knowledge of the latest development in molecular imaging for neuroscience applications.

This session will provide an overview of the latest progress in imaging neuroinflammation and synaptic density in the context of neuroscience applications.  The session will also discuss the latest progress in the integration of the complementary information obtained simultaneously with PET and magnetic resonance imaging (MRI) for several neuroscience applications.  

Presentations include:

  • Imaging of neuroinflammation
  • Synaptic density Imaging
  • PET/MRI 

Nuclear Medicine in Psychiatric Diseases
This session will explore the role of PET in psychiatric disorders.

Presentations include:

  • Role of PET Molecular Imaging in Schizophrenia
  • PET Studies of Substance Abuse and Tobacco Use
  • PET in Autism Spectrum Disorders
  • Fragile X

Read with the Experts: Bring your Interesting and Challenging Cases for Discussion
The session will include 3 topics: cases on epilepsy, cases on dementia, and cases on movement disorders. Complex and/or interesting cases will be submitted by meeting participants in advance. During the session an experienced physician will present the cases to experts, who will read images and discuss the cases with the audience.

Presentations include:

  • Cases on Epilepsy
  • Cases on Dementia
  • Cases on Parkinsonism